Medimaa (Human Albumin As Macroaggregates)

Medimaa is employed in nuclear medicine to assess pulmonary blood flow and ventilation‑perfusion balance.

• Lung perfusion imaging: provides quantitative assessment of regional pulmonary blood flow during radionuclide studies.
• Ventilation‑perfusion (V/Q) scan: enables detection of perfusion defects and mismatched ventilation areas, supporting diagnosis of pulmonary embolism.
• Pulmonary embolism evaluation: assists clinicians in identifying mismatched ventilation‑perfusion regions to confirm or exclude embolic events.

• Human Albumin macroaggregates consist of microscopic particles that, when injected intravenously, become temporarily lodged in the pulmonary capillary bed. Labeled with a radionuclide, these particles emit gamma radiation that is captured by a gamma camera, producing images of pulmonary perfusion. The transient embolic effect creates a functional map of blood flow without causing permanent vascular obstruction, allowing clinicians to evaluate ventilation‑perfusion relationships.

Adverse reactions to Medimaa are generally related to its embolic nature and protein composition.

Common Side Effects

• Transient fever: mild temperature rise shortly after injection.
• Mild hypotension: temporary blood pressure drop that resolves spontaneously.
• Injection site reaction: localized redness or swelling at the IV site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction that may be life‑threatening.
• Severe hypotension: marked blood pressure decline requiring medical intervention.
• Embolic phenomena: unintended blockage of larger vessels causing organ ischemia.

When using Medimaa, clinicians should observe specific safety measures to minimize risks associated with its intravenous administration.

• Allergy assessment: verify the patient has no known hypersensitivity to human albumin or related proteins.
• Pregnancy and lactation: use only if clearly indicated, as safety data are limited.
• Fluid balance monitoring: assess renal function and avoid volume overload in susceptible patients.
• Concurrent radionuclide use: coordinate timing to ensure optimal imaging quality.
• Compatibility: dilute and administer according to manufacturer instructions using sterile diluents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medimaa may interact with certain agents, influencing its distribution or the interpretation of imaging results.

Major Interactions (Avoid)

• Radiopharmaceutical agents: co‑administration can alter perfusion imaging outcomes.
• High‑dose albumin products: combined use may increase risk of volume overload.
• Thrombolytic therapy: may enhance embolic complications during the scan.

Moderate Interactions (Monitor Closely)

• Iodinated contrast media: may affect pulmonary capillary dynamics and image quality.
• Beta‑adrenergic blockers: can mask hypotensive responses after injection.